Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SUTRO BIOPHARMA, INC.
Report date May 15, 2025 · Filed May 19, 2025
Section 16 reporting ended · disclosed 2025-05-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 160,805 |
Ending reported balance
After 2025-05-15 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2025-05-15 · Exercise / conversion · Acquired 24,438 · Balance 156,519 Row 2 · 2025-05-15 · Exercise / conversion · Acquired 11,156 · Balance 167,675 Row 3 · 2025-05-15 · Exercise / conversion · Acquired 9,125 · Balance 176,800 Row 4 · 2025-05-15 · Tax withholding · Disposed 15,995 · Balance 160,805 F1: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security · Expires 2028-03-01 | Direct | 27,312 |
Reported balance
After 2025-05-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-05-15 · Exercise / conversion · Disposed 24,438 · Balance 27,312 F2: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3: The RSUs vest as to 1/4th of the total award annually beginning on March 1, 2025, subject to continued service through each vesting date. F4: The reported transactions represent the accelerated vesting of certain of the reporting person's equity awards outstanding under the issuer's 2018 Equity Incentive Plan, in connection with his separation and transition from his position with the issuer, as previously reported by the issuer in its Current Report filed with the Securities and Exchange Commission on Form 8-K on March 13, 2025. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security · Expires 2027-03-01 | Direct | 4,594 |
Reported balance
After 2025-05-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-05-15 · Exercise / conversion · Disposed 11,156 · Balance 4,594 F2: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4: The reported transactions represent the accelerated vesting of certain of the reporting person's equity awards outstanding under the issuer's 2018 Equity Incentive Plan, in connection with his separation and transition from his position with the issuer, as previously reported by the issuer in its Current Report filed with the Securities and Exchange Commission on Form 8-K on March 13, 2025. F5: The RSUs vest as to 1/4th of the total shares annually beginning on March 1, 2024, subject to continued service through each vesting date. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security · Expires 2026-03-04 | Direct | 0 |
Reported balance
After 2025-05-15 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-05-15 · Exercise / conversion · Disposed 9,125 · Balance 0 F2: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4: The reported transactions represent the accelerated vesting of certain of the reporting person's equity awards outstanding under the issuer's 2018 Equity Incentive Plan, in connection with his separation and transition from his position with the issuer, as previously reported by the issuer in its Current Report filed with the Securities and Exchange Commission on Form 8-K on March 13, 2025. F6: The RSUs vest as to 1/4th of the total award annually beginning on March 4, 2023, subject to continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person.
F2: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.
F3: The RSUs vest as to 1/4th of the total award annually beginning on March 1, 2025, subject to continued service through each vesting date.
F4: The reported transactions represent the accelerated vesting of certain of the reporting person's equity awards outstanding under the issuer's 2018 Equity Incentive Plan, in connection with his separation and transition from his position with the issuer, as previously reported by the issuer in its Current Report filed with the Securities and Exchange Commission on Form 8-K on March 13, 2025.
F5: The RSUs vest as to 1/4th of the total shares annually beginning on March 1, 2024, subject to continued service through each vesting date.
F6: The RSUs vest as to 1/4th of the total award annually beginning on March 4, 2023, subject to continued service through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2025 Filed May 19, 2025 16:11 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 9,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-013618 · form4-05192025_080539.xml · derivative · entry 7 ALBINI EDWARD C · CIK 0001240014 · CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,125 shares Expires 2026-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The reported transactions represent the accelerated vesting of certain of the reporting person's equity awards outstanding under the issuer's 2018 Equity Incentive Plan, in connection with his separation and transition from his position with the issuer, as previously reported by the issuer in its Current Report filed with the Securities and Exchange Commission on Form 8-K on March 13, 2025. F6 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on March 4, 2023, subject to continued service through each vesting date. Read SEC document |
| May 15, 2025 Filed May 19, 2025 16:11 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 11,156 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-013618 · form4-05192025_080539.xml · derivative · entry 6 ALBINI EDWARD C · CIK 0001240014 · CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,594 Underlying: Common Stock · 11,156 shares Expires 2027-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The reported transactions represent the accelerated vesting of certain of the reporting person's equity awards outstanding under the issuer's 2018 Equity Incentive Plan, in connection with his separation and transition from his position with the issuer, as previously reported by the issuer in its Current Report filed with the Securities and Exchange Commission on Form 8-K on March 13, 2025. F5 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 1, 2024, subject to continued service through each vesting date. Read SEC document |
| May 15, 2025 Filed May 19, 2025 16:11 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 24,438 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-013618 · form4-05192025_080539.xml · derivative · entry 5 ALBINI EDWARD C · CIK 0001240014 · CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,312 Underlying: Common Stock · 24,438 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on March 1, 2025, subject to continued service through each vesting date. F4 · derivative.exercise_date: The reported transactions represent the accelerated vesting of certain of the reporting person's equity awards outstanding under the issuer's 2018 Equity Incentive Plan, in connection with his separation and transition from his position with the issuer, as previously reported by the issuer in its Current Report filed with the Securities and Exchange Commission on Form 8-K on March 13, 2025. Read SEC document |
| May 15, 2025 Filed May 19, 2025 16:11 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 15,995 | $0.88 | $14,075.60 |
DisclosureSEC source: 0001415889-25-013618 · form4-05192025_080539.xml · nonDerivative · entry 4 ALBINI EDWARD C · CIK 0001240014 · CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,805 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| May 15, 2025 Filed May 19, 2025 16:11 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 9,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-013618 · form4-05192025_080539.xml · nonDerivative · entry 3 ALBINI EDWARD C · CIK 0001240014 · CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2025 Filed May 19, 2025 16:11 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 11,156 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-013618 · form4-05192025_080539.xml · nonDerivative · entry 2 ALBINI EDWARD C · CIK 0001240014 · CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 167,675 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2025 Filed May 19, 2025 16:11 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 24,438 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-013618 · form4-05192025_080539.xml · nonDerivative · entry 1 ALBINI EDWARD C · CIK 0001240014 · CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,519 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 16:11 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 8,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-007393 · form4-03072025_090300.xml · derivative · entry 3 ALBINI EDWARD C · CIK 0001240014 · CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,750 shares Expires 2025-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on March 5, 2022, subject to continued service through each vesting date. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 16:11 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 3,594 | $1.36 | $4,887.84 |
DisclosureSEC source: 0001415889-25-007393 · form4-03072025_090300.xml · nonDerivative · entry 2 ALBINI EDWARD C · CIK 0001240014 · CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,081 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 16:11 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 8,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-007393 · form4-03072025_090300.xml · nonDerivative · entry 1 ALBINI EDWARD C · CIK 0001240014 · CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,675 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 16:14 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 9,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-007185 · form4-03062025_090345.xml · derivative · entry 3 ALBINI EDWARD C · CIK 0001240014 · CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,125 Underlying: Common Stock · 9,125 shares Expires 2026-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on March 4, 2023, subject to continued service through each vesting date. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 16:14 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 3,748 | $1.42 | $5,322.16 |
DisclosureSEC source: 0001415889-25-007185 · form4-03062025_090345.xml · nonDerivative · entry 2 ALBINI EDWARD C · CIK 0001240014 · CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,925 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 16:14 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 9,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-007185 · form4-03062025_090345.xml · nonDerivative · entry 1 ALBINI EDWARD C · CIK 0001240014 · CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,673 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 18:44 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 17,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006714 · form4-03042025_110314.xml · derivative · entry 5 ALBINI EDWARD C · CIK 0001240014 · CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,750 Underlying: Common Stock · 17,250 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on March 1, 2025, subject to continued service through each vesting date. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 18:44 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 7,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006714 · form4-03042025_110314.xml · derivative · entry 4 ALBINI EDWARD C · CIK 0001240014 · CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,750 Underlying: Common Stock · 7,875 shares Expires 2027-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 1, 2024, subject to continued service through each vesting date. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 18:44 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 10,320 | $1.59 | $16,408.80 |
DisclosureSEC source: 0001415889-25-006714 · form4-03042025_110314.xml · nonDerivative · entry 3 ALBINI EDWARD C · CIK 0001240014 · CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,548 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 18:44 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 17,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006714 · form4-03042025_110314.xml · nonDerivative · entry 2 ALBINI EDWARD C · CIK 0001240014 · CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,868 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 18:44 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 7,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006714 · form4-03042025_110314.xml · nonDerivative · entry 1 ALBINI EDWARD C · CIK 0001240014 · CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,618 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 16:21 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 8,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-007181 · form4-03072024_090345.xml · derivative · entry 5 ALBINI EDWARD C · CIK 0001240014 · CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,750 Underlying: Common Stock · 8,750 shares Expires 2025-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F5 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on March 5, 2022, subject to continued service through each vesting date. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 16:21 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Units (RSUs) · Derivative | 51,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-007181 · form4-03072024_090345.xml · derivative · entry 4 ALBINI EDWARD C · CIK 0001240014 · CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,000 Underlying: Common Stock · 51,000 shares Expires 2028-03-01 F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on March 1, 2025, subject to continued service through each vesting date. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 16:21 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (Right to Buy Common Stock) · Derivative | 68,000 | $0.00 Strike: $4.54 | $0.00 |
DisclosureSEC source: 0001415889-24-007181 · form4-03072024_090345.xml · derivative · entry 3 ALBINI EDWARD C · CIK 0001240014 · CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,000 Underlying: Common Stock · 68,000 shares Expires 2034-03-05 F2 · derivative.exercise_date: The option vests as to 2.0833% of the total award monthly, beginning on April 1, 2024, with 100% of the award being vested and exercisable on March 1, 2028, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 16:21 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 3,100 | $4.54 | $14,074.00 |
DisclosureSEC source: 0001415889-24-007181 · form4-03072024_090345.xml · nonDerivative · entry 2 ALBINI EDWARD C · CIK 0001240014 · CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,743 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 16:21 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 8,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-007181 · form4-03072024_090345.xml · nonDerivative · entry 1 ALBINI EDWARD C · CIK 0001240014 · CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,843 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2024 Filed Mar 22, 2024 16:21 UTC Amendment | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Units (RSUs) · Derivative | 69,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-008952 · form4a-03222024_080309.xml · derivative · entry 1 ALBINI EDWARD C · CIK 0001240014 · CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,000 Underlying: Common Stock · 69,000 shares Expires 2028-03-01 F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F2 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on March 1, 2025, subject to continued service through each vesting date. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 16:18 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 9,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-007012 · form4-03062024_090307.xml · derivative · entry 3 ALBINI EDWARD C · CIK 0001240014 · CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,250 Underlying: Common Stock · 9,125 shares Expires 2026-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on March 4, 2023, subject to continued service through each vesting date. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 16:18 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 3,472 | $4.79 | $16,630.88 |
DisclosureSEC source: 0001415889-24-007012 · form4-03062024_090307.xml · nonDerivative · entry 2 ALBINI EDWARD C · CIK 0001240014 · CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,093 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 16:18 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 9,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-007012 · form4-03062024_090307.xml · nonDerivative · entry 1 ALBINI EDWARD C · CIK 0001240014 · CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,565 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 16:29 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 7,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-006651 · form4-03052024_090359.xml · derivative · entry 3 ALBINI EDWARD C · CIK 0001240014 · CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,625 Underlying: Common Stock · 7,875 shares Expires 2027-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSU award vests as to 1/4th of the total award annually beginning on March 1, 2024, subject to continued service through each vesting date. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 16:29 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 3,227 | $4.95 | $15,973.65 |
DisclosureSEC source: 0001415889-24-006651 · form4-03052024_090359.xml · nonDerivative · entry 2 ALBINI EDWARD C · CIK 0001240014 · CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,440 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 16:29 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 7,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-006651 · form4-03052024_090359.xml · nonDerivative · entry 1 ALBINI EDWARD C · CIK 0001240014 · CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 16:28 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 5,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-002071 · form4-01312024_090157.xml · derivative · entry 3 ALBINI EDWARD C · CIK 0001240014 · CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,250 shares Expires 2024-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on January 29, 2021, subject to continued service through each vesting date. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 16:28 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 2,151 | $4.99 | $10,733.49 |
DisclosureSEC source: 0001415889-24-002071 · form4-01312024_090157.xml · nonDerivative · entry 2 ALBINI EDWARD C · CIK 0001240014 · CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,792 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 16:28 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 5,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-002071 · form4-01312024_090157.xml · nonDerivative · entry 1 ALBINI EDWARD C · CIK 0001240014 · CFO AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,943 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 16:22 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 8,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016736 · doc4.xml · derivative · entry 7 ALBINI EDWARD C · CIK 0001240014 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 8,750 shares Expires 2025-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F6 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 5, 2022, subject to continued service through each vesting date. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 16:22 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 9,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016736 · doc4.xml · derivative · entry 6 ALBINI EDWARD C · CIK 0001240014 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,375 Underlying: Common Stock · 9,125 shares Expires 2026-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F5 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 4, 2023, subject to continued service through each vesting date. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 16:22 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Unit (RSU) · Derivative | 31,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016736 · doc4.xml · derivative · entry 5 ALBINI EDWARD C · CIK 0001240014 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,500 Underlying: Common Stock · 31,500 shares Expires 2027-03-01 F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 1, 2024, subject to continued service through each vesting date. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 16:22 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy Common Stock) · Derivative | 47,000 | $0.00 Strike: $5.79 | $0.00 |
DisclosureSEC source: 0001209191-23-016736 · doc4.xml · derivative · entry 4 ALBINI EDWARD C · CIK 0001240014 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,000 Underlying: Common Stock · 47,000 shares Expires 2033-02-28 F3 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on April 1, 2023, with 100% of the total shares vested and exercisable on March 1, 2027, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 16:22 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 6,588 | $5.79 | $38,144.52 |
DisclosureSEC source: 0001209191-23-016736 · doc4.xml · nonDerivative · entry 3 ALBINI EDWARD C · CIK 0001240014 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,693 F2 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 16:22 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 8,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016736 · doc4.xml · nonDerivative · entry 2 ALBINI EDWARD C · CIK 0001240014 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,281 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 16:22 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 9,125 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016736 · doc4.xml · nonDerivative · entry 1 ALBINI EDWARD C · CIK 0001240014 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,531 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 17:12 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionStock Option (right to buy) · Derivative | 45,698 | $0.00 Strike: $5.81 | $0.00 |
DisclosureSEC source: 0001209191-23-009236 · doc4.xml · derivative · entry 2 ALBINI EDWARD C · CIK 0001240014 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,698 shares Expires 2023-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 17:12 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 45,698 | $5.81 | $265,413.98 |
DisclosureSEC source: 0001209191-23-009236 · doc4.xml · nonDerivative · entry 1 ALBINI EDWARD C · CIK 0001240014 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,406 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 17:19 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 5,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-005751 · doc4.xml · derivative · entry 3 ALBINI EDWARD C · CIK 0001240014 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 Underlying: Common Stock · 5,250 shares Expires 2024-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on January 29, 2021, subject to continued service through each vesting date. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 17:19 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 2,140 | $7.50 | $16,050.00 |
DisclosureSEC source: 0001209191-23-005751 · doc4.xml · nonDerivative · entry 2 ALBINI EDWARD C · CIK 0001240014 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,708 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 17:19 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 5,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-005751 · doc4.xml · nonDerivative · entry 1 ALBINI EDWARD C · CIK 0001240014 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,848 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2022 Filed Mar 7, 2022 19:09 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 8,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016846 · doc4.xml · derivative · entry 5 ALBINI EDWARD C · CIK 0001240014 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,250 Underlying: Common Stock · 8,750 shares Expires 2025-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F5 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 5, 2022, subject to continued service through each vesting date. Read SEC document |
| March 05, 2022 Filed Mar 7, 2022 19:09 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 3,145 | $8.17 | $25,694.65 |
DisclosureSEC source: 0001209191-22-016846 · doc4.xml · nonDerivative · entry 2 ALBINI EDWARD C · CIK 0001240014 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,598 F2 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| March 05, 2022 Filed Mar 7, 2022 19:09 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 8,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-016846 · doc4.xml · nonDerivative · entry 1 ALBINI EDWARD C · CIK 0001240014 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,743 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. Read SEC document |
| March 04, 2022 Filed Mar 7, 2022 19:09 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Unit (RSU) · Derivative | 36,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016846 · doc4.xml · derivative · entry 4 ALBINI EDWARD C · CIK 0001240014 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,500 Underlying: Common Stock · 36,500 shares Expires 2026-03-04 F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 4, 2023, subject to continued service through each vesting date. Read SEC document |
| March 04, 2022 Filed Mar 7, 2022 19:09 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy Common Stock) · Derivative | 42,000 | $0.00 Strike: $8.17 | $0.00 |
DisclosureSEC source: 0001209191-22-016846 · doc4.xml · derivative · entry 3 ALBINI EDWARD C · CIK 0001240014 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2032-03-03 F3 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on April 4, 2022, with 100% of the total shares vested and exercisable on March 4, 2026, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.